Cytokinetics Sees IBD RS Rating Improve To 74

By Investor's Business Daily | Jul 19, 2024 at 03:00 AM EST

IBD's RS Rating measures a stock's price performance, with high ratings indicating potential growth. Cytokinetics shows strength but is out of buy range. Look for new entry points. Check for upcoming financial reports and use RS Rating to assess stock performance.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.